Tafoxiparin is protected by several patent families

Dilafor´s drug product candidate tafoxiparin, is protected by several patent families with potential patent expiries in 2043. Substance patent protection for tafoxiparin has been granted worldwide. Further patent applications are also on file, covering additional aspects of Dilafor´s development programme.


Up to 50 % of all term pregnant women are planned for start of labor with conventional treatments, which carries a high risk of complications for both mothers and infants.